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ABSTRACT
In this study we describe the immunogenicity results from a subset of older people (N D 5187) who
participated in a Phase 3 randomized, observer-blinded trial of AS03-TIV versus TIV (FluarixTM)
(ClinicalTrials.gov, NCT00753272). Participants received one dose of AS03-TIV or TIV in each study year and
antibody titers against the vaccine strains were assessed using hemagglutination-inhibition (HI) assay at
21 d and 180 d post-vaccination in each vaccine group in the 2008/09 (Year 1) and 2009/10 (Year 2)
inﬂuenza seasons. Manufacturing consistency of 3 lots of AS03-TIV for HI antibody responses in Year 1 was
a co-primary objective.
In a post-hoc analysis, a statistical regression model included 4830 subjects in whom immunogenicity
and laboratory-conﬁrmed attack rate data were available; the analysis was performed to assess HI
antibody titers against A/H3N2 as a correlate of protection for laboratory-conﬁrmed A/H3N2 inﬂuenza.
AS03-TIV and TIV elicited strong HI antibody responses against each vaccine strain 21 d post-vaccination
in both years. The manufacturing consistency of 3 lots of AS03-TIV was demonstrated. In both years and
each vaccine group, HI antibody responses were lower for A/H1N1 than the other vaccine strains. Day 180
seroconversion rates (proportion with 4-fold increase in titer compared with pre-vaccination titer) in
Year 1 in the AS03-TIV and TIV groups, respectively, were 87.7% and 74.1% for A/H3N2, 69.7% and 59.6%
for inﬂuenza B, and 58.3% and 47.4% for A/H1N1.
The post-hoc statistical model based on A/H3N2 attack rates and HI antibody titers estimated that a 4-
fold increase in post-vaccination titers against A/H3N2 was associated with a 2-fold decrease in the odds
of A/H3N2 infection.
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Introduction
Observational studies suggest that the effectiveness of trivalent
inactivated inﬂuenza vaccine (TIV) is reduced in older people
compared with younger populations, and this is thought to be
associated with age-related decline in immune functions, which
impairs the ability to resist inﬂuenza infection and respond to
vaccination.1,2 However, because it is unethical to use a placebo
vaccine in high-risk populations, reliable estimates of absolute
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efﬁcacy of existing inﬂuenza vaccines in older people are lack-
ing.3 Strategies to improve the immunogenicity of TIVs with
the aim of reducing inﬂuenza-related morbidity and mortality
in older people includes the use of high-doses of hemagglutinin
antigen (HA), intradermal administration, and formulation
with adjuvant systems.4-8
Although newer inﬂuenza vaccine formulations for use in
older people have been shown to increase immunogenicity,4-8
the vaccine efﬁcacy of candidate vaccines can only be
assessed relative to the existing standard of care. Most
recently, in a randomized study of 31,989 people aged
65 years, high-dose (180 mg HA) vs. standard dose (45 mg
HA) TIV (FluzoneTM ; Sanoﬁ Pasteur) was found to be better
for the prevention of any inﬂuenza infection, with a relative
efﬁcacy of 24.2%.9 However, in a randomized, multinational
trial of 43,000 people aged 65 years (Inﬂuence65 trial),
AS03-adjuvanted TIV (AS03-TIV) versus TIV (FluarixTM ;
GlaxoSmithKline) did not signiﬁcantly prevent inﬂuenza A
and/or B, with a relative efﬁcacy of 12.0%.10 The predomi-
nant virus in the Inﬂuence65 trial was A/H3N2, and post-hoc
analyses showed signiﬁcant relative efﬁcacy for AS03-TIV vs.
TIV for the prevention of inﬂuenza A/H3N2 infection-
related clinical outcomes including all-cause death and pneu-
monia. The relative vaccine efﬁcacy for AS03-TIV versus
TIV for the prevention of A/H3N2 was 22.0% (95% CI: 5.68
to 35.49).10
Here we describe the immunogenicity for AS03-TIV vs.
TIV in people aged 65 years based on a subset of the pop-
ulation from the Phase 3 Inﬂuence65 trial. In addition, we
assessed the relationship between A/H3N2 infection rates
and vaccine-induced antibody titers against A/H3N2 to
evaluate the HI antibody titers as a correlate of vaccine
efﬁcacy.
Results
Study population
The immunogenicity subset included 5187 and 4417 subjects
in Year 1 and 2, respectively (Fig. 1). In this subset, the mean
age at ﬁrst vaccination was 73.2 y (range 65–95 years) in the
AS03-TIV group, and 73.4 y (range 65–100 years) in the TIV
group.
In the total vaccinated cohort of the Inﬂuence65 trial, a
total of 43,695 subjects were vaccinated in Year 1 and 34,141
also received a second vaccination in Year 2. The study was
initiated on 15 September 2008 and the data lock point in
Year 1 was 23 April 2010, and in Year 2 the data lock point
was 3 May 2011, respectively. Study cohorts and reasons for
withdrawal from the total vaccinated cohort are shown in
Figure 1.
Lot-to-lot consistency
The AS03-TIV per-protocol consistency cohort comprised
1612 subjects of which 540 received lot 1, 538 lot 2, and 534 lot
3. At Day 21 after the ﬁrst AS03-TIV vaccination, the 2-sided
95% Conﬁdence Interval (CI) of the adjusted geometric mean
Figure 1. Participant ﬂow chart. Note: AS03, tocopherol, oil-in-water emulsion-based Adjuvant System; CI, conﬁdence intervals; TIV, inactivated trivalent inﬂuenza vaccine;
Year 1, 2008/09; Year 2, 2009/10.
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titer (GMT) ratios for each lot-to-lot comparison was within
the pre-deﬁned interval for consistency for each vaccine strain
(Table 1). The seroconversion rate (SCR) on Day 21 in subjects
who received AS03-TIV lot 1, 2, and 3 ranged from 55.6% to
58.3% against A/H1N1, from 85.5% to 87.4% against A/H3N2
and from 65.3% to 72.2% against the B strain.
Immunogenicity at Day 0 and Day 21
Before vaccination in Year 1, in the AS03-TIV and TIV groups,
respectively, 69.3% and 68.0% were seropositive (titer 1:10)
for A/H1N1, 64.7% and 65.0% were seropositive for A/H3N2,
and 95.0% and 94.2% were seropositive for the inﬂuenza B
strain included in the vaccine (Victoria lineage).
Descriptive immunogenicity in Year 1 and Year 2 is shown
in Table 2. At Day 21 in Year 1, GMTs in the AS03-TIV and
TIV groups, respectively, were 89.1 and 69.9 for A/H1N1,
285.6 and 172.3 for A/H3N2, and 633.5 and 484.8 for Inﬂuenza
B (Fig. 2). A similar pattern of response as that observed in
Year 1 was observed for GMTs in Year 2 against inﬂuenza A
strains, whereas GMTs in Year 2 were lower for inﬂuenza B at
199.2 and 171.3 in the AS03-TIV and TIV groups, respectively.
In Year 1, at Day 21 in the AS03-TIV group, the SCRs and
SPRs for the three strains were 58.3% and 85.9%, respec-
tively, and in the TIV group were 47.4% and 76.1%, respec-
tively. At Day 21 in Year 2, in the AS03-TIV group, the SCRs
and SPRs were 40.2% and 86.2%, respectively, and in the
TIV group were 34.1% and 79.7%, respectively (Table 2).
Immunogenicity persistence at Day 180
In the per-protocol immunogenicity persistence cohort in Year
1 at Day 180 in the AS03-TIV group, the SPRs against A/
H1N1, A/H3N2, and inﬂuenza B were 55.2%, 78.4%, 99.6%,
respectively, and in the TIV group were 50.2%, 69.7%, and
100.0%, respectively. In Year 2 at Day 180 in the AS03-TIV
group, the SPRs against A/H1N1, A/H3N2, and inﬂuenza B
were 47.1%, 86.2%, 93.1%, respectively, in the TIV group were
48.0%, 76.8%, and 90.4%, respectively. In Year 1 in the AS03-
TIV group at Days 21 and 180, respectively, GMTs were 75.4
and 30.4 for A/H1N1, 275.0 and 97.7 for A/H3N2, and 573.4
and 274.6 for inﬂuenza B; GMTs with in the TIV group at
Days 21 and 180, respectively, were 64.5 and 28.1 for A/H1N1,
165.0 and 64.0 for A/H3N2, and 478.5 and 262.3 for inﬂuenza
B (Fig. 3). The SCRs in the per-protocol immunogenicity per-
sistence cohort from Day 0 to 180 are shown in Figure 4. In
Year 1 at Day 180, SCRs for the 3 strains ranged between 19.8%
and 55.6% in the AS03-TIV group and between 20.8% and
39.6% in the TIV group, which was higher than SCRs observed
at Day 180 in Year 2 between 3.7% and 22.2% and between
3.4% and 0.3%, respectively.
HI antibody titers as a correlate of protection
against A/H3N2
A total of 4828 subjects from the immunogenicity cohort were
included in the correlates of protection analysis, of which most
subjects were recruited in the Czech Republic (22.7%), Ger-
many (22.1%), and the US (21.7%). During the 2008/09 peak
season, inﬂuenza epidemic intensity varied between countries,
and A/H3N2 was the predominant circulating strain in 12 out
of 15 countries based on national surveillance and attack rates
in the study (Table 3). A descriptive analysis of the HI antibody
titers is shown in Table 4.
At baseline, 3244/4814 (67.39%) subjects in the immunoge-
nicity subset had a HI titer of 1:40 against A/H3N2, and
1570/4814 (32.61%) had a titer of <1:40.
Of the 2422 subjects in the AS03-TIV group, A/H3N2 infection
was conﬁrmed in 18 subjects (attack rate: 0.74%), and of the 2408
subjects in the TIV group, A/H3N2 infection was conﬁrmed in 42
subjects (attack rate: 1.74%). A total of 2939 subjects were recruited
from regions with low or moderate viral circulation, and 1891 sub-
jects from regions with high viral circulation. Among subjects
exposed to low or moderate viral circulation, there were 20 con-
ﬁrmed cases of A/H3N2 infection (attack rate: 0.68%), and among
those exposed to high viral circulation, there were 40 conﬁrmed
cases of A/H3N2 infection (attack rate: 2.12%).
The frequency of A/H3N2 cases and post-vaccination HI
antibody titers against A/H3N2 is shown in Figure 5. Among
391/4830 (8.1%) subjects with post-vaccination HI titers of
<1:40, 18/391 (4.6%) subjects had PCR-conﬁrmed A/H3N2
infection; among 4439/4830 (91.9%) subjects with post-vacci-
nation titers of 1:40, 42/4439 (0.95%) had PCR-conﬁrmed A/
H3N2 infection.
Post-vaccination log titers and season strength were selected
for inclusion in the model, suggesting that there is a relationship
between post-vaccination HI antibody titers against A/H3N2 and
the risk of A/H3N2 infection (Table 5). The model allowed us to
estimate that a 4-fold difference in HI titer was associated with a
53% (95% CI: 41%, 63%) decrease in the infection odds. The odds
ratio estimate associated to the season strength (high versus low/
moderate) was 0.283 (95% CI: 0.164, 0.488). Risk of A/H3N2
infection in a low/moderate and a high season as a function of
post-vaccination log-titers are shown in Figure 6. Removing sea-
son strength from the model had little impact on the estimated
relationship between post-vaccination HI antibody titers against
A/H3N2 and the risk of A/H3N2 infection.
Table 1. Hemagglutination-inhibition-based adjusted GMT ratios at Day 21 after
vaccination for 3 lots of AS03-TIV in the per-protocol consistency cohort.
Adjusted GMT
Adjusted GMT
ratio (95% CI)
Lot 1 (N D 539) Lot 2 (N D 536) Lot 1/lot 2
A/H1N1 82.6 83.8 0.99 (0.87, 1.12)
A/H3N2 271.9 287.5 0.95 (0.82, 1.09)
B strain 649.0 600.8 1.08 (0.97, 1.20)
Lot 2 (N D 536) Lot 3 (N D 532) Lot 2/lot 3
A/H1N1 83.7 93.6 0.89 (0.78, 1.02)
A/H3N2 283.7 271.8 1.04 (0.90, 1.21)
B strain 594.4 605.6 0.98 (0.88, 1.09)
Lot 1 (N D 539) Lot 3 (N D 532) Lot 1/lot 3
A/H1N1 82.6 93.6 0.88 (0.78, 1.00)
A/H3N2 269.8 273.4 0.99 (0.85, 1.14)
B strain 646.2 609.9 1.06 (0.95, 1.18)
Adjusted GMT, geometric mean titer adjusted for baseline titer of the 2 compared
lots; AS03, tocopherol-based oil-in-water emulsion Adjuvant System; CI, conﬁ-
dence interval; TIV, inactivated trivalent inﬂuenza vaccine; N, number of subjects
with pre- and post-vaccination results available.
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Discussion
AS03-TIV and TIV elicited strong HI antibody responses
against each vaccine strain in people aged 65 years. The
manufacturing consistency of 3 lots of AS03-TIV based on
HI antibody responses was demonstrated. Twenty-one days
after one dose of vaccine in Year 1 and after another dose
of vaccine in Year 2, the immunogenicity of both AS03-TIV
and TIV fulﬁlled licensure criteria for inﬂuenza vaccines.11
Here we describe the immunogenicity ﬁndings from the
Phase 3 Inﬂuence65 trial, which was based on a subset of
5187 subjects, of which 60% of in each vaccine group were
Figure 2. Day 21 hemagglutination-inhibition-based GMTs in the per-protocol immunogenicity cohort in Year 1 (A) and Year 2 (B). Note: AS03, tocopherol, oil-in-water
emulsion-based Adjuvant System; CI, conﬁdence intervals; TIV, inactivated trivalent inﬂuenza vaccine; GMT, geometric mean titer; N, number of subjects in the cohort
with data available at time-point; Year 1, 2008/09; Year 2, 2009/10; Inﬂuenza A strains were A/Brisbane/59/2007 (H1N1 strain) and A/Uruguay/716/2007 (H3N2 strain);
Inﬂuenza B strains were B/Brisbane/3/2007 (Victoria lineage) in Year 1 and B/Brisbane/60/2008 (Yamagata lineage) in Year 2.
Figure 3. Day 21 and 180 hemagglutination-inhibition-based GMTs in the per-protocol immunogenicity persistence cohorts in Year 1 (A) and Year 2 (B). Note: AS03,
tocopherol, oil-in-water emulsion-based Adjuvant System; CI, conﬁdence intervals; TIV, inactivated trivalent inﬂuenza vaccine; N, number of subjects in the cohort with
data available at time-point; GMT, geometric mean titer; Year 1, 2008/09; Year 2, 2009/10; Inﬂuenza A strains were A/Brisbane/59/2007 (H1N1 strain) and A/Uruguay/716/
2007 (H3N2 strain); Inﬂuenza B strains were B/Brisbane/3/2007 (Victoria lineage) in Year 1 and B/Brisbane/60/2008 (Yamagata lineage) in Year 2.
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seropositive (HI antibody titer 1 :10) before vaccination in
Year 1. After vaccination, HI antibody responses were
robust, although some strain dependent differences were
observed.
After vaccination in Year 1, SCRs against the B strain (Victo-
ria lineage) were 67.9% with AS03-TIV and 59.2% with TIV,
and were lower in Year 2 against the B strain (Yamagata lineage)
at 48.7% and 36.9%, respectively. For the B strain, the 95% CI
for the SPR was 60% and for the SCR was 30% (fulﬁlling
licensure criteria) in both vaccine groups in both years at Day
21, and SCRs and SPRs remained above this threshold at Day
180 in Year 1. We observed differences in HI antibody responses
against the 2 inﬂuenza A strains. Immune responses overall were
weakest against A/H1N1 in the AS03-TIV and TIV groups at
Day 21 in Year 1 (SCRs, 58.3% and 47.4%, respectively). Day 21
SCRs against A/H3N2 were robust in the AS03-TIV and TIV
Figure 4. Day 21 and 180 hemagglutination-inhibition-based SCRs in the per-protocol immunogenicity persistence cohorts in Year 1 (A) and Year 2 (B). Note: AS03,
tocopherol, oil-in-water emulsion-based Adjuvant System; CI, conﬁdence intervals; TIV, inactivated trivalent inﬂuenza vaccine; N, number of subjects in the cohort with
data available at time-point; Year 1, 2008/09; Year 2, 2009/10; Inﬂuenza A strains were A/Brisbane/59/2007 (H1N1 strain) and A/Uruguay/716/2007 (H3N2 strain); Inﬂuenza
B strains were B/Brisbane/3/2007 (Victoria lineage) in Year 1 and B/Brisbane/60/2008 (Yamagata lineage) in Year 2; SCR, seroconversion rate deﬁned as the proportion of
seronegative subjects at baseline with post-vaccination titer of 1:40, or pre-vaccination titer of 1:10 and 4-fold increase post-vaccination.
Table 3. Season strength, circulating inﬂuenza viruses, and attack rates by country.
Attack rate (%) in the total cohort in
each country Dominant strain
Country
Number subjects in country in the
immunogenicity subset (% of total
cohort)
A/H3N2 season
strengthy AS03-TIV TIV National Study
Belgium 134 (2.77%) high 1.83 1.84 H3N2 H3N2
Canada 130 (2.69%) moderate 1.47 1.10 H1N1/Inﬂuenza B H3N2/Inﬂuenza B
Czech Republic 1096 (22.69%) high 1.41 1.88 H3N2 H3N2
Estonia 141 (2.92%) low 1.25 0.90 H3N2/Inﬂuenza B H3N2
France 128 (2.65%) high 1.62 1.42 H3N2 H3N2
Germany 1068 (22.11%) moderate 1.03 1.39 H3N2/Inﬂuenza B H3N2
Mexico 130 (2.69%) low 1.04 0.99 H3N2/H1N1 Inﬂuenza B
Netherlands 126 (2.61%) high 2.68 3.44 H3N2 H3N2
Norway 133 (2.75%) high 0.88 1.44 H3N2 H3N2
Poland 144 (2.98%) high 2.62 2.69 H3N2 H3N2
Romania 143 (2.96%) low 1.47 1.08 H3N2 H3N2
Russia 140 (2.90%) low 1.06 1.28 H3N2/H1N1 H3N2
Taiwan 139 (2.88%) low 0.27 0.40 H1N1/Inﬂuenza B H1N1
United Kingdom 130 (2.69%) high 1.18 1.80 H3N2 H3N2
United States 1048 (21.70%) moderate 0.51 0.78 H1N1/Inﬂuenza B Inﬂuenza B
yBased on national surveillance data and study surveillance based on the review of the Adjudication Steering Committee for the Inﬂuenza peak season (2008–2009
inﬂuenza season)
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groups in Year 1 (87.7% and 74.1%, respectively), yet were
slightly lower in Year 2 (53.0% and 43.9%, respectively). In both
years in both vaccine groups, licensure criteria were fulﬁlled at
Day 21 for A/H3N2, and SPRs remained above the licensure
threshold at Day 180 in both years in both vaccine groups. SCRs
for A/H3N2 at Day 180 remained above the Day 21 licensure
threshold in Year 1, but not in Year 2.
A possible explanation for the lower SCR against A/H3N2 in
Year 2 than in Year 1 is the effect of baseline antibody titers on
immune responses to vaccination. Various studies have shown
that pre-vaccination titers, resulting from natural exposure or
previous vaccination, can affect the immunogenicity of
subsequent seasonal inﬂuenza vaccines.12-15 In our study, in the
immunogenicity cohort, in Year 1, the rate of inﬂuenza vacci-
nation in the previous season was 75% and in Year 2 was 100%
(i.e. due to study vaccination during Year 1), and during both
season in the study A/H3N2 was the predominant circulating
strain. It is possible that vaccination in Year 1 or natural expo-
sure to A/H3N2 could have had a negative impact on the
immune response in Year 2.
The immunogenicity subset included subjects from all 15
countries in the Inﬂuence65 trial and the wide regional
spread of the population is a strength of the trial. However,
66.5% of the immunogenicity subset were recruited in Ger-
many (n D 1068), Czech Republic (n D 1096), and US (n
D 1048), which was based the need to limit variation in the
population in order to compare immunogenicity between
vaccine lots to assess the consistency of the manufacturing
process. The results of the Inﬂuence65 trial suggest that
AS03-TIV improved protection compared with TIV against
inﬂuenza A infection (secondary analysis, relative efﬁcacy
17.5%) and inﬂuenza A/H3N2 infection in particular (post-
hoc analysis, relative efﬁcacy 22.0%).10 In the immunogenic-
ity subset, the A/H3N2 attack rate was 0.74% in the AS03-
TIV group and 1.74% in the TIV group. The estimated rela-
tive efﬁcacy between the vaccine groups in the immunoge-
nicity subset appeared high (»57%), and well above the
point estimate (12.16%) in the overall study population. No
explanation for this phenomenon has been found.
Table 4. Descriptive statistics HI titers against A/H3N2 in the immunogenicity
subset.
Time point N (n missing) Mean HI titer (SD) Min – max HI titer
Day 0
AS03-TIV 2456 42.63 (94.995) (5–1810)
TIV 2447 42.48 (89.791) (5–1280)
Day 21
AS03-TIV 2456 638.6 (1112.343) (5–20480)
TIV 2447 449.3 (968.72) (5–20480)
Day 180
AS03-TIV 280 (2176) 265.57 (492.528) (5–5120)
TIV 274 (2173) 174.44 (300.594) (5–2560)
AS03, tocopherol-based oil-in-water emulsion Adjuvant System; TIV, inactivated tri-
valent inﬂuenza vaccine SD, standard deviation; HI, hemagglutination inhibition
Figure 5. Number of subjects in each titer category and number of A/H3N2 cases (A) and proportion of subjects in each titer category with PCR-conﬁrmed A/H3N2 infec-
tion (B) in the immunogenicity subset.
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The relatively high rate of antigenic drift observed with A/
H3N2 is thought to be associated with an increased risk of
complications and death by this inﬂuenza subtype compared
with inﬂuenza B strains and A/H1N1 in older adults.16-18 For
example, based on analysis of US hospital discharge records
collected for 22 seasons (1979–2001), severe inﬂuenza out-
comes were much more frequent in the elderly population than
among younger adults and children, and the rates of primary
pneumonia and inﬂuenza-related hospitalization tended to be
higher overall in years when A/H3N2 predominated.16 In the
2008/09 inﬂuenza season in the countries in our study, A/
H3N2 was the predominant strain, including high epidemic
intensity in Czech Republic and moderate epidemic intensity in
Germany. In an analysis of inﬂuenza strains in the total vacci-
nated cohort from the Inﬂuence65 trial, 498 virus samples were
subtyped including A/H3N2 (380 viruses), A/H1N1 (29
viruses), B/Yamagata (23 viruses), and B/Victoria (66 viruses),
and all but 3 of the A/H3N2 strains were matched to the vac-
cine strains based on HA1 domain nucleic acid sequence.19
Current licensure criteria for inﬂuenza vaccines are based on
immunogenicity measures that assume post-vaccination HI
antibody titers above a deﬁned threshold will be sufﬁcient to
prevent inﬂuenza in the population.11 However, it has been
suggested that whereas HI titers may offer a guide to vaccine
efﬁcacy, absolute titer may not correlate directly with protec-
tion, and serological measures may not be an adequate surro-
gate for protection.20-23 The HI antibody titer threshold of 1:40
is generally recognized as corresponding to a 50% reduction in
the risk of inﬂuenza, which is based on a challenge study in
adults conducted by Hobson et al in 1972.24
A previous modeling study based on 15 studies reporting HI
titers corresponding to different inﬂuenza vaccine strains, sup-
ports the reliability of antibody titers as correlates of protection
in adults; the study showed that whereas protection increased
at titers 1:10, a titer of 1:30 was associated with a 50% reduc-
tion in the risk of inﬂuenza, and a titer of 1:50 was 90% protec-
tive.25 A clinical study of adults aged 18 to 49 y showed that the
cut-off titer for protection against A/H1N1 was as low as
1:30,26 although other studies suggest that the thresholds for
protection are higher in children and older adults. For example,
in children aged 6 to 72 months, a titer of 1:110 was correlated
with a 50% protection rate against A/H3N2, and 80% protec-
tion was achieved at 1:330.20 In a study of adults aged
50 years among which post-vaccination HI titers in the popu-
lation overall were above levels considered to be protective,
among subjects with conﬁrmed A/H3N2 infection, 90.9% had
extremely low HI titers (1:9) against A/H3N2.27
However, in elderly populations the currently available vac-
cine efﬁcacy data in people aged 65 years are from the active-
controlled Inﬂuence65 trial, and a large randomized trial of
high-dose vs. standard dose TIV (FluzoneTM; Sanoﬁ Pasteur),
which included about 31,989 subjects in the 2011/12 and 2012/
13 seasons in the US and Canada. The correlates of protection
analysis was based on a randomly selected subset and showed
that HI titres of 1:40 corresponded with 50% protection for A/
H3N2 cases that were antigenically matched to the vaccine,
whereas HI titres of 1:203 to 1:437 were needed for 50%
Table 5. Parameter estimates of the logistic regression model obtained after vari-
able selection.
Parameter Estimate (SE) 95% Conﬁdence Interval
Intercept ¡2.28 (0.44) [¡3.15, ¡1.42]
Post-vaccination log titers ¡1.27 (0.20) [¡1.66, ¡0.87]
Season Strength 1.04 (0.28) [0.50, 1.59]
SE, standard error
Figure 6. A/H3N2 HI antibody titer and estimated risk of A/H3N2 inﬂuenza infec-
tion overall (A), in a low/moderate season (B) and in a high season (C) in the immu-
nogenicity subset. Note: Points represent the observed proportions of cases and
the dotted curve show 95% conﬁdence interval; HI, hemagglutination-inhibition.
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protection in A/H3N2 cases with poor vaccine match.23 In the
Inﬂuence65 correlates of protection analysis we assessed the
distribution of HI titers and the distribution of A/H3N2 cases,
and showed that among subjects with post-vaccination HI titers
of <1:40, 4.6% had A/H3N2 infection, compared with 0.95% of
subjects with post-vaccination titers of 1:40. Next we per-
formed a logistic regression, and conﬁrmed a relationship
between post-vaccination HI antibody titers against A/H3N2
and the risk of A/H3N2 infection. A 4-fold difference in post-
vaccination HI antibody titers against A/H3N2 was associated
with a 2-fold decrease in the odds of A/H3N2 infection. How-
ever, it should be noted that the population was elderly, and
these ﬁndings may not extrapolate to younger populations.
It has been previously suggested that HI-based surrogates
may be unsuitable for older people because they do not take
into account declines in cell-mediated immune responses.7 It is
recognized that multiple components of immune function are
affected by the aging process including impairment of CD4 and
CD8 effector and memory T cell responses, and as such, assess-
ments of immune responses to vaccines in older populations
should include both humoral and cell-mediated responses, with
the clinical goal of increasing both to levels which are correlated
with protection.7,11,14,20,29
Although our modeling analysis provides an important
insight into correlates of protection in elderly people, a lim-
itation of the study was that the Inﬂuence65 trial was not
initially planned to include a correlate of protection evalua-
tion. A barrier to evaluating correlates of protection is that
most inﬂuenza vaccine trials are not powered for this type
of assessment. Moreover, in an active control trial, a large
proportion of subjects may have high titers and be well pro-
tected whereas assessment of a correlate involves contrast-
ing those with low titers and high rates of disease with
those with high titers and low rates of disease, and there
may be relatively few of the former in an active control trial
such as inﬂuenza vaccine trials in elderly populations.
In summary, in this large randomized study of people aged
65 years, AS03-TIV and TIV elicited strong antibody responses
against each vaccine strain 21 d post-vaccination and antibody
persistence 6 months post-vaccination were strongest for A/
H3N2 and lowest for A/H1N1. A model based on HI titers and
A/H3N2 attack rates suggests that a single threshold value for
antibody titers within the current deﬁnition of seroprotection
may not demonstrate adequate protection in older people.
Methods
Design and objectives
This Phase 3, randomized, observer-blind study was conducted
to assess the efﬁcacy, immunogenicity and safety of an AS03-
adjuvanted TIV compared with a non-adjuvanted TIV during
the 2008/09 (Year 1) and 2009/10 (Year 2) inﬂuenza seasons.
The co-primary objective of vaccine efﬁcacy of AS03-TIV versus
TIV for the prevention of inﬂuenza A and/or B in Year 1, and
secondary objectives including vaccine efﬁcacy against clinical
outcomes, and reactogenicity and a safety summary, have been
reported elsewhere.32 Here we describe the co-primary objective
of immunogenic lot-to-lot consistency of 3 lots of AS03-TIV,
and secondary immunogenicity measures of HI antibody titers
at Day 21 and Day 180 post-vaccination in each year.
Here we report immunogenicity in a subset of the Phase
3 population including 5187 subjects from Belgium, Canada,
Czech Republic, Estonia, France, Germany, Mexico, Nor-
way, Poland, Romania, Russia, Taiwan, the Netherlands, the
United Kingdom, and the United States. The study protocol
was approved by Independent Ethics Committees and/or
local or central Institutional Review Boards, and was con-
ducted in accordance with Good Clinical Practice, the prin-
ciples of the Declaration of Helsinki, and all regulatory
requirements of participating countries. ClinicalTrials.gov,
NCT00753272.
Subjects
Eligible subjects were men and women aged 65 years who
were not hospitalized or bedridden, and were without acute ill-
ness. Subjects were community-based or lived in a retirement
home that allowed mixing in the community. Exclusion criteria
included subjects who received any inﬂuenza vaccine after Feb-
ruary 2008, or vaccination in the previous 3 y with an investiga-
tional adjuvanted candidate seasonal or pandemic inﬂuenza
vaccine. The study protocol was amended in September 2009
to permit vaccination against the human A(H1N1)pdm09 pan-
demic strain if given at least 14 d before or after study vaccina-
tion. All subjects provided informed written consent.
Vaccines
The vaccines were AS03-TIV (0.7 mL) or TIV (0.5 mL,
FluarixTM); the Adjuvant System contained squalene and 5.93 mg
a-tocopherol in an oil-in-water emulsion (AS03B formulation).
Both vaccines were manufactured by GlaxoSmithKline Biological
SA (Rixensart, Belgium). Each vaccine dose contained 15 mg of
hemagglutinin antigen (HA) for each of theWorld Health Organi-
zation’s recommended strains (total 45 mg HA); in both seasons
the inﬂuenza A strains were A/Brisbane/59/2007 (H1N1 strain)
and A/Uruguay/716/2007 (H3N2 strain), and the inﬂuenza B
strain was B/Brisbane/3/2007 (Victoria lineage) in 2008/09, and B/
Brisbane/60/2008 (Yamagata lineage) in 2009/10.
Randomization was implemented with an internet-based sys-
tem provided by GSK. A blocking scheme was used to randomly
assign subjects (1:1) at each site to receive AS03-TIV or TIV. Sub-
jects who were assigned to receive AS03-TIV were further ran-
domly assigned (1:1:1) to one of 3 vaccine lots. Subjects were
stratiﬁed by age: 65–74 y or 75 y or older. Within both age strata,
the randomization algorithm used a minimisation procedure
accounting for study center and whether participants lived in a
retirement home. Some centers only recruited subjects for the
immunogenicity subset, in some centers the ﬁrst recruited sub-
jects were entered in the immunogenicity subset until the subset
was fulﬁlled, and some centers did not recruit in the immunoge-
nicity subset.
Vaccines were administered intramuscularly in the deltoid
muscle region of the non-dominant arm by non-blinded per-
sonnel who took no further part in the study procedures;
observers and subjects were blind to vaccine allocation. Subjects
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were scheduled to receive one dose of vaccine in Year 1 and a
second dose of the same vaccine in Year 2.
Objectives
The co-primary objectives of the Phase 3 study were the assess-
ment of relative efﬁcacy of AS03-TIV and TIV and the assess-
ment of the lot-to-lot consistency of 3 consecutive lots of
AS03-TIV in a subset of subjects. Lot-to-lot consistency was
based on HI assay antibody titers (Geometric Mean Titer
[GMT] ratio) against each vaccine strain at Day 21 after the
ﬁrst vaccination in the consistency cohort. Secondary objectives
were to assess HI antibody titers at Day 0 and Day 21 for all
subjects in the immunogenicity subset (immunogenicity
cohort), and at Day 180 in each year in a further subset of sub-
jects (immunogenicity persistence cohort).
Immunogenicity
Antibody titers against the 3 vaccine strains in each year were
measured using a validated micro-titer HI assay as previously
described.28 HI assay-based antibody responses were described
as the anti-log of the arithmetic mean of the log-10 transformed
titers (GMTs), seroprotection rate (SPR; proportion of subjects
with post-vaccination titer 1:40), seroconversion rate (SCR;
proportion of seronegative subjects at baseline with post-vacci-
nation titer of 1:40, or pre-vaccination titer of 1:10 and 4-
fold increase post-vaccination); and seroconversion factor
(SCF; geometric mean of the ratio between pre-vaccination and
post-vaccination reciprocal HI titers). Subjects were considered
seropositive if they had a pre-vaccination antibody titer of
1:10 for a given vaccine strain.
Statistics
Reactogenicity and safety during the post-vaccination period
were to be assessed in a target sample of 6000 subjects (reacto-
genicity and safety cohort), in order to have around 3000 sub-
jects exposed to AS03-TIV in the safety/reactogenicity analysis.
Of the 6000 subjects, 5226 were to be included in the immuno-
genicity cohort and 600 of these subjects were included in the
immunogenicity persistence cohort. The target sample size for
the co-primary lot-to-lot consistency analysis was 1749 of the
immunogenicity cohort, including 583 subjects per vaccine lot.
In order to limit variability in the population for the lot-to-lot
consistency assessment, these 1749 subjects were recruited in 3
predeﬁned countries (Czech Republic, Germany and US).
Additional subjects for the immunogenicity cohort were
recruited over the remaining 12 countries participating in the
study, in order to have a representation of each country in case
unexpected vaccine efﬁcacy ﬁndings would have warranted
immunogenicity assessment per country.
Some centers only recruited subjects for the immunogenicity
subset, in some centers the ﬁrst recruited subjects were entered in
the immunogenicity subset until the subset was fulﬁlled, and some
centers did not recruit in the immunogenicity subset. Given the
additional operational workload of obtaining serum samples and
the need to limit variation in the population to compare immuno-
genicity between vaccine lots to assess the consistency of the
manufacturing process, this cohort was recruited from centers in
Germany (n D 1068), Czech Republic (n D 1096), and US (n D
1048). The centers were selected based on their high recruitment
potential. The immunogenicity persistence subset was allocated
from the subjects in the lot-to-lot consistency cohort.
Per-protocol (PP) analyses were performed for each cohort:
consistency cohort; immunogenicity cohort (Year 1 and Year
2); and immunogenicity persistence cohort (Year 1 and Year
2), including subjects who met eligibility criteria, complied
with the protocol, received any dose of either vaccine, and for
whom data were available for a given endpoint. Immunogenic-
ity data (GMTs, SPRs, SCRs, and SCFs) were summarized using
descriptive statistics with a 2-sided 95% conﬁdence interval
(CI) based on the PP cohorts. GMT ratios were calculated for
each AS03-TIV lot comparison (lot 1 vs. lot 2; lot 2 versus lot 3;
lot 1 vs. lot 3) using an ANCOVA model. The ANCOVA model
included the vaccine group as ﬁxed effect and the pre-vaccina-
tion log-transformed titer as regressor. Lot-to-lot consistency
was demonstrated if for each vaccine strain the adjusted GMT
ratio of the 2-sided 95% CI was within 0.67 and 1.5.
Correlate of protection analysis
In a post-hoc analysis, a statistical regression model was used to
assess the relationship between post-vaccination HI antibody
titers against A/H3N2 and laboratory-conﬁrmed A/H3N2
inﬂuenza attack rates in the Phase 3, vaccine efﬁcacy trial
(Inﬂuence65). Among the 43,695 subjects in the Inﬂuence65
trial, there were 590 PCR-conﬁrmed cases of inﬂuenza, includ-
ing 375 cases caused by A/H3N2, which was the most common
inﬂuenza virus detected overall.10
Descriptive analysis
All of the covariates used in the analysis were: male or female,
age, seasonal inﬂuenza vaccination history within previous
2 years, A/H3N2 infection status by the end of the study season,
pre- (Day 0) and post-vaccination (Day 21) HI antibody titers
against A/H3N2, pre-vaccination A/H3N2 seroprotection status
(HI titer 1:40), vaccine received (AS03-TIV or TIV), and
‘strong season’ or ‘low/moderate season’. Inﬂuenza infection
exposure (season strength) was based on national surveillance
data and attack rates in the study, as assessed by the Adjudica-
tion Steering Committee for the inﬂuenza peak season in the
Inﬂuence65 trial. Season strength was used as an indicator of the
subjects’ exposure to the virus. The committee included experts
in the ﬁeld of inﬂuenza and inﬂuenza vaccination who were
independent of the study investigators and the study sponsor.
Peak season was deﬁned as the period during the study with the
highest incidence of any matching or drift inﬂuenza strain rela-
tive to the vaccine strains, which was determined post-hoc based
on national surveillance data and/or study data.
A descriptive analysis of these variables was performed. For
continuous variables, the number of observations, mean, stan-
dard deviation, and minimum and maximum values were com-
puted. For HI antibody titers, GMTs and their coefﬁcient of
variation were also calculated after a log10 transformation. Fre-
quency statistics, including counts and proportions were
obtained for the categorical variables. The proportion of
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subjects with laboratory-conﬁrmed A/H3N2 inﬂuenza was cal-
culated for each dilution factor of the post-vaccination HI anti-
body response against A/H3N2.
Statistical modeling
The probability of an A/H3N2 disease occurrence was modeled
with a logistic regression considering pre-vaccination immunity
state (titer 1:40 deﬁned as ‘protected’), Day 21 post-vaccina-
tion A/H3N2 log titers, gender, history of vaccination (vaccina-
tion 1 and 2 y before study start), vaccine received, and season
strength as explanatory variables. A manual stepwise variable
selection was performed based on the Bayesian information cri-
terion to select the best combination of covariates to describe
the disease occurrence. Odds deﬁned as the probability of
experiencing an A/H3N2 disease occurrence divided by the
probability of not experiencing an A/H3N2 disease occurrence
were estimated for several subject proﬁles from this model.
Those proﬁles were compared by computing odds ratios.
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